Johnson & Johnson
Change company Symbol lookup
Select an option...
JNJ Johnson & Johnson
QIAN Qiansui International Group Co Ltd
BV Brightview Holdings Inc
PFE Pfizer Inc
MP Mp Materials Corp
WFG West Fraser Timber Co Ltd
MDT Medtronic PLC
ATMR^ Altimar Acquisition Corp II
AEG Aegon NV
MGP MGM Growth Properties LLC
Go

Health Care : Pharmaceuticals | Large Cap Value
Company profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Closing Price
$164.96
Day's Change
-2.12 (-1.27%)
Bid
--
Ask
--
B/A Size
--
Day's High
167.08
Day's Low
164.22
Volume
(Average)
Volume:
7,389,922

10-day average volume:
6,860,986
7,389,922

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

7:41 am ET May 1, 2021 (Accesswire) Print

LOS ANGELES, CA / ACCESSWIRE / May 1, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ:ACAD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Image: https://www.accesswire.com/users/newswire/images/643701/0cec307a5d6dfb7bcb8e044151f12a81.jpg

Investors who purchased the Company's securities between June 15, 2020 and April 4, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before June 18, 2021.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Acadia submitted an sNDA for pimavanserin to the FDA that suffered from design and statistical problems. The pimavanserin sNDA did not contain the support for its approval despite the Company telling investors that it did. As a result, the FDA was unlikely to approve the sNDA as it was submitted. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Acadia, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm

Brian Schall, Esq.,

www.schallfirm.com

Office: 310-301-3335

info@schallfirm.com

SOURCE: The Schall Law Firm

View source version on accesswire.com:

https://www.accesswire.com/643701/SHAREHOLDER-ACTION-NOTICE-The-Schall-Law-Firm-Reminds-Investors-of-a-Class-Action-Lawsuit-Against-ACADIA-Pharmaceuticals-Inc-and-Encourages-Investors-with-Losses-in-Excess-of-100000-to-Contact-the-Firm

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.